|Bid||0.00 x 900|
|Ask||14.00 x 1400|
|Day's Range||12.54 - 13.50|
|52 Week Range||9.87 - 32.32|
|Beta (3Y Monthly)||1.24|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
If you are building a properly diversified stock portfolio, the chances are some of your picks will perform badly. But...
MacroGenics (MGNX) delivered earnings and revenue surprises of 32.29% and -39.74%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?
Today we'll do a simple run through of a valuation method used to estimate the attractiveness of MacroGenics, Inc...
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on July 10) CONMED Corporation (NASDAQ: CNMD ) Eidos Therapeutics ...
Incyte (INCY) inks a licensing deal with Zai Lab to develop and commercialize INCMGA0012 for hematology and oncology indications in Greater China.
As discussed in my column on Monday, small biotechs that need to raise money over the next 12 months as they ramp up sales on recently approved products have been particularly hit hard. Developmental concerns with no approved products are doing much better provided they have adequate cash runways. Data support what should be a successful New Drug Application (NDA) in the near future, but the information wasn't as overwhelming positive as some investors evidently hoped for as MacroGenics shares saw some profit taking in the days after the event.
These companies could make a big difference in how the disease is diagnosed and treated. And their stocks could make a big difference for long-term investors.
In 2001 Scott Koenig was appointed CEO of MacroGenics, Inc. (NASDAQ:MGNX). This report will, first, examine the CEO...
Biotech companies Iovance Biotherapeutics, MacroGenics and Mirati Therapeutics were among the winners in a slew of data for cancer treatments released late Wednesday. Stocks rose Thursday.
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on May 15) Applied Therapeutics Inc (NASDAQ: APLT ) (debuted on ...
It's getting close to 13F filing season and several stocks such as Amazon and JPMorgan are in the spotlight because of it. Furthermore, Microsoft is also in the spotlight due to an unrelated issue concerning some of its software. Without further ado, let's analyze why traders are watching each stock and how the smart money […]
MacroGenics (MGNX) delivered earnings and revenue surprises of -4.21% and -15.69%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for the stock?
On a per-share basis, the Rockville, Maryland-based company said it had a loss of 99 cents. The results fell short of Wall Street expectations. The average estimate of eight analysts surveyed by Zacks ...
NextCure Inc., a Beltsville biotech with one anticancer drug in clinical testing and several local biotech veterans in its leadership ranks, has filed to go public three years after its founding. The company, which has applied to trade on the Nasdaq Global Market under the ticker symbol "NXTC," plans to offer 5 million shares to the public, with up to 750,000 additional shares available to its underwriters. It estimates an offering price of $14 to $16 per share, bringing a potential total haul to $80.5 million to $92 million if all shares are sold in the initial public offering.
In Monday's column, we recapped the first quarter for the overall market as well as the biotech sector. It will be a quarterly performance that we are unlikely to match for some time. As noted then, it presented mid-stage data at the American Association for Cancer Research conference in Atlanta this week.
Want to participate in a research study? Help shape the future of investing tools and earn a $60 gift card! It is doubtless a positive to see that the MacroGenics, Inc. (NASDAQ:MGNX) share price has gained some 46% in the last thr...
Want to participate in a short research study? Help shape the future of investing tools and receive a $20 prize! The big shareholder groups in MacroGenics, Inc. (NASDAQ:MGNX) have powerRead More...